Institut für Immunologie

2023

Einrichtungsstatistik
Forschungsprojekte20
Publikationen11

Forschungsprojekte

Projektleiter: Univ.-Prof. Dr. Matthias Barz, Univ.-Prof. Dr. Tobias Bopp

Entwicklung und Erbrobung polypept(o)idischer Nanopartikel zur Aufhebung der Monozyten-vermittelten Immunsuppresion beim malignen Melanom - SFB1066/3 TP B8

Synthese und gerichtete Weiterentwicklung etablierter Systeme. Erprobung des Therapieansatzes im humanisierten MISTRG Maus-Melanommodell. Systemübergreifende Analyse der anti-tumoralen Immunantwort nach NP-vermittelter cAMP Modulation im humanisierten Mausmodell.

Laufzeit: 2021-2025
Projektleiter: Univ.-Prof. Dr. Matthias Barz, Prof. Dr. Ugur Sahin

Nanopartikuläre mRNA-Trägersysteme zur Reprogrammierung von Immunzellpopulationen - SFB1066/3 TP B12

Synthese von Systemen zum funktionellen mRNA Transfer. Screening-Assaysysteme weiterentwickeln. In vivo Testung des spezifischen und funktionalen mRNA-Transfers. Konzept zu Therapien. GMP-komforme Herstellung und klinische Translatierbarket.

Laufzeit: 2021-2025
Projektleiter: Univ.-Prof. Dr. Tobias Bopp

Analyse der GPCR65-vermittelten metabolischen Kommunikation in der Tumormikroumgebung

SFB1292/2, TP01

Laufzeit: 2022-2025
Projektleiter: Univ.-Prof. Dr. Tobias Bopp

CK2 als molekularer Schalter, der Immunität und Toleranz durch APC-abhängige Induktion von Treg-Zellen reguliert

TRR355/1, A09

Laufzeit: 2023-2026
Projektleiter: Univ.-Prof. Dr. Tobias Bopp

Funktionelle Relevanz von CD18 und regulatorischen T-Zellen in der Haut

TRR 156/2, B11

Laufzeit: 2019-2023
Projektleiter: Univ.-Prof. Dr. Tobias Bopp

Integriertes Graduiertenkolleg

SFB1292/2, MKG

Laufzeit: 2022-2025
Projektleiter: Univ.-Prof. Dr. Tobias Bopp

Interaktionen von myeloiden und regulatorischen T Zellen in Thrombus Entstehung und Auflösung

TRR355/1, A10

Laufzeit: 2023-2026
Projektleiter: Univ.-Prof. Dr. Michael Delacher

Dynamik, epigenetische Signaturen und modulierende Faktoren der Differenzierung von Gewebe-Treg-Zellen

TRR355/1, A01

Laufzeit: 2023-2026
Projektleiter: Univ.-Prof. Dr. Michael Delacher

Induktion eines Gewebeheilungsprogramms als Immunevasionsstrategie in Tumoren und chronischen Infektionen

SFB1292/2, TP19

Laufzeit: 2022-2025
Projektleiter: Univ.-Prof. Dr. Michael Delacher

Treg Commons

TRR355/1, Z02

Laufzeit: 2023-2026
Projektleiter: Dr. Ute Distler

Regulation und Ziele der viralen Immunevasion

SFB1292/2, TP11

Laufzeit: 2022-2025
Projektleiter: Univ.-Prof. Dr. Stephan Grabbe, Univ.-Prof. Dr. Hansjörg Schild

Polymer-vermittelte Tumor-Immuntherapie durch in situ Aktivierung von antigenpräsentierenden Zellen - SFB1066/3 TP B4

Weiterentwicklung bioabbaubarer Nanogel-Vakzine zur Etablierung antigen-spezifischer Antitumor-Immunantworten. Ex vivo Analyse der durch DC-targetierende NP induzierten Immunantwort. Optimierung der tumorspezifischen Immunantwort.

Laufzeit: 2021-2025
Projektleiter: PD Dr. Niels Lemmermann, PD Dr. Ute Distler

Regulation and host targets of viral immune evasion

The evasion of intrinsic, innate, and adaptive immune responses is a common feature of tumors and chronic viral infections. Various viruses interfere with the presentation of antigenic peptides by MHC class-I to limit recognition of infected cells. Additionally, ligands of activating and inhibitory receptors are regulated to downmodulate the natural killer (NK) cell response. Another option for viruses to evade the immune response is a direct interference with intracellular pathways that induce an antiviral state of infected cells is.
In eons of co-evolution, the species-adapted cytomegaloviruses (CMVs) have evolved multiple strategies dedicated to subvert the immune response. On the other hand, for the respective host it was required to evolve mechanisms to overrule viral immune evasion mechanisms to limit disease pathology by keeping the virus in a balanced state. This results in viral latency, a state during which the immune system suppresses productive infection but fails to clear viral genomes from the host tissues.
Most of the research done so far focused on the viral side, whereas much less is known on how the host counters viral immune evasion and to which extent viral and host proteins interact. One known countermeasure is the exhaustion of the inhibitory capacity of viral immune evasion proteins by interferon (IFN)-enhanced antigen processing and presentation. Another possibility is the regulation of viral immune evasion gene expression by the host. Understanding how virus and host interact and how the host manages to keep viruses under control even under conditions of viral immune evasion may reveal new concepts and targets to enhance immune recognition also of malignant cells.
The well-characterized model of murine CMV (mCMV) has been decisive for the discovery of CMV immune evasion mechanisms and made it feasible to study their roles in vivo. Most of the known immune evasion genes of mCMV cluster in two gene families, the m02 (m02-m16) and the m145 (m141-m158) family. In our first objective, we will comprehensively map the interactome of mCMV immune evasion proteins. We will generate a library of recombinant viruses that allows, after in vivo biotinylation, the targeted pulldown of each viral immune evasion protein and its respective interaction partners. Subsequently, the interacting proteins will be identified by quantitative mass spectrometry (MS) enabling the identification of yet unknown binding partners and novel pathways of immune evasion.
The swiss-army-knife m152/gp40, which is an MHC-I-like molecule, targets multiple cellular proteins to subvert intrinsic, innate, and adaptive immune responses. m152 not only modulates the NKG2D ligand RAE1 and classical MHC-I complexes inhibiting the recognition of infected cells by NK and CD8 T cells, respectively, but also interacts with STING to slow down the induction of type-I IFNs. Evidence from the current funding period indicates that the transcription of m152 is controlled by an 'IFN regulatory factor element (IRFE)' located in the promoter region of the m152 gene. During acute infection, the IRFE is targeted by suppressive IFN response factors (IRFs) resulting in a delayed transcription of m152. This identified the m152 promotor region as a target for host countermeasures. Further, our results indicate a cell type-specific suppression of m152 transcription. In contrast, we have first experimental evidence that the IRFE acts as an activating regulator of m152 transcription during viral latency. In objectives two and three, we now propose experiments to analyze the regulation and function of the regulatory elements in the m152 promoter region during acute and latent mCMV infection.

Laufzeit: 2022-2025
Projektleiter: Univ.-Prof. Dr. Volker Mailänder, Univ.-Prof. Dr. Stefan Tenzer

Von der Nanomaterial-Oberfläche zur Funktion - multifunktionelle PEGylierung, Targeting und in vivo Proteomics -SFB1066/3 TP Q6

Proteomics für die Untersuchung zellulärer Veränderungen nach NP-Applikation und zur Analyse der Protein Corona. Untersuchung der Abhängigkeit der Protein-Corona von der Oberflächenstruktur der Nanocarrier durch multifunktionale PEGylierung und Oberflächenmodifikation mit Fokus auf Clusterin und andere Stealth Proteine. Optimierung des Zelltyp-selektiven Tragetings in vivo durch gezielte Modifikation der Protein Corona, sowie mittels Fab-Antikörper, Nanobodies und multifunktionalem Targeting.

Laufzeit: 2021-2025
Projektleiter: Dr. Hans Christian Probst, Univ.-Prof. Dr. Hansjörg Schild

Mikrobiom induzierte, tonische Typ I Interferone in der Kontrolle zytotoxischer T Zell Antworten gegen Tumore, chronische und akute Virusinfektionen

SFB1292/2, TP13

Laufzeit: 2022-2025
Projektleiter: Dr. Hans Christian Probst, Univ.-Prof. Dr. Hansjörg Schild

Subpopulationen dendritischer Zellen der Haut und äußere Einflüsse in der Induktion und Modulation von T-Zell Antworten in der Haut

TRR 156/2, B02

Laufzeit: 2019-2023
Projektleiter: Prof. Dr. Markus Radsak, Dr. Sabine Muth

Type-I Interferons – a double-edged sword in myeloproliferative neoplasms and chronic viral infections (SFB 1292, TP21)

Type-I Interferons (IFNs) are a very efficient treatment of Myeloproliferative Neoplasms (MPNs) and can even induce long-term remissions. However, the mechanisms of type I IFN on hematopoiesis in MPNs are only poorly understood. Given the pleiotropic effects of type I IFNs we hypothesize that type I IFN driven activation of immune and stromal cells also contributes to therapeutic effects. Using two different mouse models for MPNs we will investigate the immunological mechanisms by which type I IFNs attack malignant hematopoietic stem cells. We will correlate our findings with clinical samples from MPN patients. As altered hematopoiesis also occurs in many chronic viral infections as a potential mechanism of immune evasion we aim to clarify how type I IFNs affect hematopoiesis in MPNs and chronic viral infections in parallel.

Laufzeit: 2022-2025
Projektleiter: Univ.-Prof. Dr. Hansjörg Schild

Zentrale Aufgaben des Sonderforschungsbereichs

SFB1292/2, Z02

Laufzeit: 2022-2025
Projektleiter: Univ.-Prof. Dr. Stefan Tenzer

Integrierte OMICS, Bioinformatik und Morpho-molekulare Immunomonitoring Plattform (SFB1292, Q01)

SFB1292/2, Q01

Laufzeit: 2022-2025
Projektleiter: Univ.-Prof. Dr. Stefan Tenzer

SPP2225_Proteomik

DFG TE 599/9-1

Laufzeit: 2021-2024

Publikationen

Backer Ronald A., Probst Hans Christian, Clausen Bjoern E.
Autoren der Einrichtung: Probst Hans Christian
Weitere Autoren des Fachbereichs: Backer Ronald A., Clausen Bjoern E.
Classical DC2 subsets and monocyte-derived DC: Delineating the developmental and functional relationship
EUROPEAN JOURNAL OF IMMUNOLOGY. 2023; 53 (3): Review
Datensatz in Web of Science®

Bersching Katharina, Michna Thomas, Tenzer Stefan, Jacob Stefan
Autoren der Einrichtung: Michna Thomas, Tenzer Stefan
Data-Independent Acquisition (DIA) Is Superior for High Precision Phospho-Peptide Quantification in Magnaporthe oryzae
JOURNAL OF FUNGI. 2023; 9 (1): Article
Datensatz in Web of Science®

Cox Eva-Maria, El-Behi Mohamed, Ries Stefanie, Vogt Johannes F., Kohlhaas Vivien, Michna Thomas, Manfroi Benoit, Al-Maarri Mona, Wanke Florian, Tirosh Boaz, Pondarre Corinne, Lezeau Harry, Yogev Nir, Mittenzwei Romy, Descatoire Marc, Weller Sandra, Weill Jean-Claude, Reynaud Claude-Agnes, Boudinot Pierre, Jouneau Luc, Tenzer Stefan, Distler Ute, Rensing-Ehl Anne, Koenig Christoph, Staniek Julian, Rizzi Marta, Magerus Aude, Rieux-Laucat Frederic, Wunderlich F. Thomas, Hoevelmeyer Nadine, Fillatreau Simon
Seniorautoren: Hoevelmeyer Nadine, Fillatreau Simon
Autoren der Einrichtung: Michna Thomas, Tenzer Stefan, Distler Ute
Weitere Autoren des Fachbereichs: Cox Eva-Maria, Vogt Johannes F., Wanke Florian, Mittenzwei Romy, Hoevelmeyer Nadine
AKT activity orchestrates marginal zone B cell development in mice and humans
CELL REPORTS. 2023; 42 (4): Article
Datensatz in Web of Science®

Garlapati Venkata, Molitor Michael, Michna Thomas, Harms Gregory S., Finger Stefanie, Jung Rebecca, Lagrange Jeremy, Efentakis Panagiotis, Wild Johannes, Knorr Maike, Karbach Susanne, Wild Sabine, Vujacic-Mirski Ksenija, Muenzel Thomas, Daiber Andreas, Brandt Moritz, Gori Tommaso, Milting Hendrik, Tenzer Stefan, Ruf Wolfram, Wenzel Philip
Seniorautoren: Ruf Wolfram, Wenzel Philip
Autoren der Einrichtung: Michna Thomas, Tenzer Stefan
Weitere Autoren des Fachbereichs: Garlapati Venkata, Molitor Michael, Harms Gregory S., Finger Stefanie, Jung Rebecca, Lagrange Jeremy, Efentakis Panagiotis, Wild Johannes, Knorr Maike, Karbach Susanne, Wild Sabine, Vujacic-Mirski Ksenija, Muenzel Thomas, Daiber Andreas, Brandt Moritz, Gori Tommaso, Ruf Wolfram, Wenzel Philip
Targeting myeloid cell coagulation signaling blocks MAP kinase/TGF-beta 1-driven fibrotic remodeling in ischemic heart failure
JOURNAL OF CLINICAL INVESTIGATION. 2023; 133 (4): Article
Datensatz in Web of Science®

Kirschner Friederike, Arnold-Schild Danielle, Leps Christian, Lacki Mateusz Krzysztof, Klein Matthias, Chen Yannic, Ludt Annekathrin, Marini Federico, Kucuk Can, Stein Lara, Distler Ute, Sielaff Malte, Michna Thomas, Riegel Kristina, Rajalingam Krishnaraj, Bopp Tobias, Tenzer Stefan, Schild Hansjoerg
Autoren der Einrichtung: Kirschner Friederike, Arnold-Schild Danielle, Leps Christian, Lacki Mateusz Krzysztof, Klein Matthias, Chen Yannic, Kucuk Can, Stein Lara, Distler Ute, Sielaff Malte, Michna Thomas, Bopp Tobias, Tenzer Stefan, Schild Hansjoerg
Weitere Autoren des Fachbereichs: Ludt Annekathrin, Marini Federico, Rajalingam Krishnaraj
Modulation of cellular transcriptome and proteome composition by azidohomoalanine-implications on click chemistry-based secretome analysis
JOURNAL OF MOLECULAR MEDICINE-JMM. 2023: Article
Datensatz in Web of Science®

Klaus Tanja, Wilson Alicia, Fichter Michael, Bros Matthias, Bopp Tobias, Grabbe Stephan
Autoren der Einrichtung: Wilson Alicia, Bopp Tobias
Weitere Autoren des Fachbereichs: Klaus Tanja, Fichter Michael, Bros Matthias, Grabbe Stephan
The Role of LFA-1 for the Differentiation and Function of Regulatory T Cells-Lessons Learned from Different Transgenic Mouse Models
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24 (7): Review
Datensatz in Web of Science®

Picard Felix Simon Ruben, Lutz Veronika, Brichkina Anna, Neuhaus Felix, Ruckenbrod Teresa, Hupfer Anna, Raifer Hartmann, Klein Matthias, Bopp Tobias, Pfefferle Petra Ina, Savai Rajkumar, Prinz Immo, Waisman Ari, Moos Sonja, Chang Hyun-Dong, Heinrich Stefan, Bartsch Detlef K., Buchholz Malte, Singh Shiv, Tu Mengyu, Klein Lukas, Bauer Christian, Liefke Robert, Burchert Andreas, Chung Ho-Ryun, Mayer Philipp, Gress Thomas M., Lauth Matthias, Gaida Matthias, Huber Magdalena
Autoren der Einrichtung: Klein Matthias, Bopp Tobias
Weitere Autoren des Fachbereichs: Waisman Ari, Moos Sonja, Heinrich Stefan, Gaida Matthias
IL-17A-producing CD8(+) T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts
GUT. 2023: Article
Datensatz in Web of Science®

Pielenhofer Jonas, Meiser Sophie Luise, Gogoll Karsten, Ciciliani Anna-Maria, Denny Mark, Klak Michael, Lang Berenice M. M., Staubach Petra, Grabbe Stephan, Schild Hansjoerg, Radsak Markus P. P., Spahn-Langguth Hilde, Langguth Peter
Autoren der Einrichtung: Schild Hansjoerg
Weitere Autoren des Fachbereichs: Lang Berenice M. M., Staubach Petra, Grabbe Stephan, Radsak Markus P. P.
Quality by Design (QbD) Approach for a Nanoparticulate Imiquimod Formulation as an Investigational Medicinal Product
PHARMACEUTICS. 2023; 15 (2): Article
Datensatz in Web of Science®

Silva-Vilches Cinthia, Bolduan Vanessa, Alabdullah Mohamad, Steinbrink Kerstin, Probst Hans Christian, Enk Alexander, Mahnke Karsten
Autoren der Einrichtung: Probst Hans Christian
Topical Application of Adenosine A2-Type Receptor Agonists Prevents Contact Hypersensitivity Reactions in Mice by Affecting Skin Dendritic Cells
JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2023; 143 (3): 408-+ Article
Datensatz in Web of Science®

Sohl Julian, Hartmann Ann-Kathrin, Hahlbrock Jennifer, Bartneck Joschka, Stassen Michael, Klein Matthias, Bros Matthias, Grabbe Stephan, Marini Federico, Woods Kevin, Guezguez Borhane, Mack Matthias, Schild Hansjoerg, Muth Sabine, Melchior Felix, Probst Hans Christian, Langguth Peter, Radsak Markus P. P.
Autoren der Einrichtung: Sohl Julian, Bartneck Joschka, Stassen Michael, Klein Matthias, Schild Hansjoerg, Muth Sabine, Melchior Felix, Probst Hans Christian, Radsak Markus P. P.
Weitere Autoren des Fachbereichs: Bros Matthias, Grabbe Stephan, Marini Federico
Dithranol as novel co-adjuvant for non-invasive dermal vaccination (vol 7, 112, 2022)
NPJ VACCINES. 2023; 8 (1): Correction
Datensatz in Web of Science®

Ziegler Nicole, Cortes-Lopez Mariela, Alt Francesca, Sprang Maximilian, Ustjanzew Arsenij, Lehmann Nadine, El Malki Khalifa, Wingerter Arthur, Russo Alexandra, Beck Olaf, Attig Sebastian, Roth Lea, Koenig Julian, Paret Claudia, Faber Joerg
Autoren der Einrichtung: Attig Sebastian
Weitere Autoren des Fachbereichs: Ziegler Nicole, Alt Francesca, Ustjanzew Arsenij, Lehmann Nadine, El Malki Khalifa, Wingerter Arthur, Russo Alexandra, Beck Olaf, Roth Lea, Paret Claudia, Faber Joerg
Analysis of RBP expression and binding sites identifies PTBP1 as a regulator of CD19 expression in B-ALL
ONCOIMMUNOLOGY. 2023; 12 (1): Article
Datensatz in Web of Science®